BRAIN TUMOR LIBRARY
Anaplastic astrocytoma18
48




Home > Brain tumor library > Diffuse astrocytic and oligodendroglial tumors > Anaplastic astrocytoma




Case reports
Classification
Diagnosis and evaluation
Epidemiology and risk factors
Etiology, pathogenesis and pathology
Follow-up and quality of life
Integrative medicine
Overall management
Prognosis and outcomes
Treatment





Case reports



BONE METASTASES



Li ZG, Mu HY.
Extracranial bone metastases from recurrent anaplastic astrocytoma on FDG PET/CT: A case report a care-compliant article.
Medicine (Baltimore). 2017 Jun;96(23):e7123. doi: 10.1097/MD.0000000000007123.
Source | Abstract | Full text | Similar articles



LONG-TERM DAILY TEMOZOLOMIDE



Zhou Z, Howard TA, Villano JL.
Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma.
Cancer Chemother Pharmacol. 2017 Aug 8. doi: 10.1007/s00280-017-3415-5. [Epub ahead of print]

Source | Abstract | Full text | Similar articles





Prognosis and outcomes



OVERVIEW



Shin JY, Diaz AZ.
Anaplastic astrocytoma: prognostic factors and survival in 4807 patients with emphasis on receipt and impact of adjuvant therapy.
J Neurooncol. 2016 Jul 11. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



TEMOZOLOMIDE



Strowd RE, Abuali I, Ye X, Lu Y, Grossman SA.
The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.
J Neurooncol. 2016 Mar;127(1):165-71. doi: 10.1007/s11060-015-2028-2. Epub 2016 Jan 4.
Source | Abstract | Full text | Similar articles





Treatment




Schiff D.
Benefit with adjuvant chemotherapy in anaplastic astrocytoma.
Lancet. 2017 Aug 8. pii: S0140-6736(17)31477-0. doi: 10.1016/S0140-6736(17)31477-0. [Epub ahead of print]
Comment on: van den Bent MJ et al, Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.
Source | Abstract | Full text | Similar articles | Synopsis



**

Malmström A, Poulsen HS, Grønberg BH, Stragliotto G, Hansen S, Asklund T, Holmlund B, Łysiak M, Dowsett J, Kristensen BW, Söderkvist P, Rosell J, Henriksson R; Nordic Clinical Brain Tumor Study Group (NCBTSG).
Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.
Acta Oncol. 2017 Jul 4:1-10. doi: 10.1080/0284186X.2017.1332780. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM.
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.
Lancet. 2017 Aug 8. pii: S0140-6736(17)31442-3. doi: 10.1016/S0140-6736(17)31442-3. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Wu J, Zou T, Bai HX, Li X, Zhang Z, Xiao B, Nasrallah M, Karakousis G, Cao Y, Zhang PJ, Yang L.
Comparison of chemoradiotherapy with radiotherapy alone for "biopsy only" anaplastic astrocytoma.
Oncotarget. 2017 Apr 26. doi: 10.18632/oncotarget.17441. [Epub ahead of print]
Source | Abstract | Full text | Similar articles